Already a Patient? Connect on My IU Health
- Biography
- Insurance
- Locations
- Specialties & Details
- Ratings & Reviews
- Clinical Trials
- Related Stories
Biography
Dr. Shadia I. Jalal specializes in Cancer Treatment for Multi-D Oncology Clinic. Dr. Jalal earned her medical degree from the University of Jordan. She also completed an internship, residency, and fellowship at IU School of Medicine.
Dr. Jalal currently has a rating of 4.8 stars out of 5 with over 50 ratings. Patients say that she is careful, outstanding, and easy to talk to. In a recent five-star review, a patient remarked: "Very professional and friendly."
Dr. Jalal's office is at Multi-D Oncology Clinic, 535 Barnhill Dr, Indianapolis, IN 46202.
Insurance
Insurance plans accepted by this provider are below.
Note: Although this listing was accurate at the time of posting, insurances change regularly, and insurance plans listed may not be accepted at all office locations for this provider. Please confirm with your insurance company that this provider is covered by your plan before your appointment.
Locations
Specialties & Details
Specialties:
Hematology - Oncology
Conditions & Treatments:
Thoracic Cancer, Lung Cancer, Esophageal Cancer
Education
School of Medicine:
University of Jordan
Internship:
IU School of Medicine
Residency:
IU School of Medicine
Fellowship:
IU School of Medicine
Hospitals & Affiliations
Hospital Privileges:
IU Health Methodist/IU Health University
Physician Group:
IU Health Medical Group
Research
Related Services
Ratings & Reviews
Clinical Trials
Explore the ongoing clinical trials this provider is involved in and learn about the eligibility requirements for each one. Search the clinical trial directory to find additional clinical trials.
A Pilot Study Evaluating a Novel Biodynamic Imaging (BDI) Method in Predicating Response to Chemotherapy in Locoregional Esophageal Cancer
View DetailsAdjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
View DetailsRandomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
View DetailsRelated Stories
Breast cancer researcher learns firsthand about lung cancer
Both professionally and personally, Alesha Arnold ...